誉衡药业上涨8.01%，报3.91元/股

Group 1 - The core viewpoint of the news highlights the recent stock performance of Yuheng Pharmaceutical, which saw an increase of 8.01% on July 31, reaching a price of 3.91 yuan per share with a trading volume of 8.85 billion yuan and a turnover rate of 11.38%, resulting in a total market capitalization of 87.81 billion yuan [1] - Yuheng Pharmaceutical, based in Harbin, Heilongjiang Province, is a modern pharmaceutical company that integrates research, production, and sales, initially focusing on orthopedic treatments and expanding into cardiovascular and other therapeutic areas, establishing a product cluster that includes cardiovascular, musculoskeletal, and nutritional medications [1] - The company emphasizes strict quality management and international innovation, having established production bases and marketing systems that comply with GMP and GSP standards, while actively developing CMO platforms and chronic disease services, aiming to become a leading pharmaceutical enterprise in China with an international perspective [1] Group 2 - As of May 30, Yuheng Pharmaceutical had 107,100 shareholders, with an average of 19,600 circulating shares per shareholder [2] - For the first quarter of 2025, Yuheng Pharmaceutical reported a revenue of 551 million yuan, a year-on-year decrease of 7.06%, while the net profit attributable to shareholders was 60.25 million yuan, reflecting a year-on-year increase of 15.24% [2]